Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024Business Wire • 09/08/24
Savara to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire • 09/03/24
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024Business Wire • 08/15/24
Savara Reports Second Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 08/12/24
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common StockBusiness Wire • 06/28/24
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Business Wire • 06/26/24
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Business Wire • 06/26/24
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024Business Wire • 05/19/24
Savara Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 05/09/24
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024Business Wire • 04/08/24
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business UpdateBusiness Wire • 03/07/24
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Business Wire • 12/21/23